4th international workshop on adverse drug reactions and lipodystrophy in hiv: San Diego, California, USA 22 25 September 2002

Expert Opinion on Drug Safety

Volumn 2, Issue 1, 2003, Pages 95-101

  Nolan, David ^a   Christiansen, Frank ^a  

^a ROYAL PERTH HOSPITAL   (Australia)

Author keywords

antiretroviral therapy; cardiovascular risk; hyperlactataemia; lactic acidosis; lipodystrophy; metabolic syndrome; NRTI; PI; toxicity

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PROTEINASE INHIBITOR;

BODY COMPOSITION; BONE DENSITY; CHEMICALLY INDUCED DISORDER; CONFERENCE PAPER; DRUG EFFECT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACTIC ACIDOSIS; LIPODYSTROPHY; METABOLISM;

ACIDOSIS, LACTIC; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BODY COMPOSITION; BONE DENSITY; HIV; HIV INFECTIONS; HUMANS; LIPODYSTROPHY; PROTEASE INHIBITORS;

EID: 0041883700     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2.1.95     Document Type: Conference Paper

References (49)

1. DUBE MP, ZACKIN R, TEBAS P et al.: Prospective study of regional body composition in antiretroviral-naive subjects randomized to receive zidovudine + lamivudine or didanosine + stavudine combined with nelfinavir, efavirenz, or both: A5005s, a susbstudy of ACTG 384. 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. San Diego, California, USA (2002). Abstract 27.
2. ROBBINS G, SHAFER R, SMEATON L et al.: Study of initial antiretroviral strategies for the treatment of HIV infection: a randomized 6-arm trial utilizing a factorial design. 14th International AIDS Conference. Barcelona, Spain (2002). Abstract LbOr20A.
3. NOLAN D, JAMES I, McKINNON E, MALLAL S: Effect of stavudine, zidovudine and HIV protease inhibitor therapy on subcutaneous leg fat wasting in HIVinfected males-a longitudinal study. 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. San Diego, California, USA (2002). Abstract 28.
4. CHENE G, ANGELINI E, COTTE L et al.: Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients. Clin. Infect. Dis. (2002) 34:649-657. (Pubitemid 34165328)
5. JOLY V, FLANDRE P, MEIFFREDY S et al.: Assessment of lipodystrophy in patients previously exposed to AZT, ddI, or ddC, but naive for d4T and protease inhibitors, and randomized between d4T/3TC/indinavir and AZT/3TC/indinavir (NOVAVIR trial). 8th Conference on Retroviruses and Opportunistic Infections. Chicago, USA (2002). Abstract 539.
6. LAW M, EMERY S, FRENCH M, CARR A, CHUAH J, COOPER D: Lipodystrophy and metabolic abnormalities in a cross-sectional study of participants in randomized controlled studies of combination antiretroviral therapy. 2nd International Workshop on Adverse Drug Reactions and Lipodystrophy. Toronto, Canada (2000). Abstract O28.
7. DRESCHLER H, POWDERLY WG: Switching effective antiretroviral therapy: a review. Clin. Infect. Dis. (2002) 35:1219-1230. (Pubitemid 35305870)
8. CARR A, WORKMAN C, SMITH DE et al.: Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA (2002) 288:207-215. (Pubitemid 34755281)
9. LONERGAN T, MCCOMSEY G, HESSENTHALER S et al.: Lack of recurrence of symptomatic and asymptomatic hyperlactatemia when stavudine is replaced by either abacavir or zidovudine: 48-week data. 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. San Diego, California, USA (2002). Abstract 21.
10. MCCOMSEY G, PAULSEN D, LONERGAN T et al.: Improvements in mitochondrial DNA levels after substituting ABC or ZDV for d4T in HIV-infected patients with lipoatrophy. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, California, USA (2002). Abstracts H-1929 and H-1930.
11. GARCIA-BENAYAS T, BLANCO F, DE LA CRUZ J, SORIANO V, GONZALEZLAHOZ J: Lipoatrophy improvement after switching stavudine to abacavir. 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. San Diego, California, USA (2002). Abstract 57.
12. JANNEH O, HOGGARD PG, SALES SD et al.: Intracellular disposition of zidovudine, stavudine and protease inhibitors and their metabolic effects in cultured adipocytes. 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. San Diego, California, USA (2002). Abstract 2.
13. FLINT OP, MULVEY R, WANG S, FENDERSON W, YANG Y-P, PARKER RA: Nucleoside reverse transcriptase inhibitors: no relationship between inhibition of mitochondrial DNA replication and metabolic function in an adipocyte culture model. 3rd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Athens, Greece (2001). Abstract 61.
14. SEN A, LEA-CURRIE YR, SUJKOWSKA D et al.: Adipogenic potential of human adipose derived stromal cells from multiple donors is heterogenous. J. Cellular Biochem. (2001) 81:312-319. (Pubitemid 32298263)
15. JOHN M, NOLAN D, MALLAL S: Antiretroviral therapy and the lipodystrophy syndrome. Antiviral Ther. (2001) 6:9-20. (Pubitemid 33704478)
16. GATTI AM, GUARALDI G, MIGLIORINO G et al.: Physician-patient concordance on lipodystrophy severity. 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. San Diego, California, USA (2002). Abstract 99.
17. KOTLER D, THOMPSON M, CHANG P, GERTNER J, MUURAHAINEN N: Anthropometric measures are poor surrogate markers for monitoring change in abdominal adiposity in HIV patients treated with growth hormone. 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. San Diego, California, USA (2002). Abstract 74.
18. FORD ES, GILES WH, DIETZ WH: Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA (2002) 287:356-359. (Pubitemid 34251969)
19. NOOR MA, SENEVIRATNE T, AWEEKA FT et al.: Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebocontrolled study. AIDS (2002) 16(5):F1-F8. (Pubitemid 34274457)
20. FRAYN KN: Insulin resistance, impaired postprandial lipid metabolism and abdominal obesity. A deadly triad. Med. Princ. Pract. (2002) 2(Suppl. 11):31-40. (Pubitemid 35365371)
21. MERWOOD MA, SOSMAN JM, BELLEHUMEUR JL, STEIN JH: Increased levels of post-prandial triglyceride-rich lipoproteins in patients taking HIV protease inhibitors. 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. San Diego, California, USA (2002). Abstract 51.
22. STEIN JH, KLEIN MA, BELLEHUMEUR JL et al.: Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation (2001) 104(3):257-362.
23. KRAUSS RM: Atherogenicity of triglyceride-rich lipoproteins. Am. J. Cardiol. (1998) 81:B13-B17.
24. SIMON GL, LIAPPIS AP, GRANGER SL et al.: Antiretroviral therapy-induced changes in lipoprotein subclass phenotype: comparison of protease inhibitor and nonnucleoside reverse transcriptase inhibitor regimens. 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. San Diego, California, USA (2002). Abstract 14.
25. VAN DER VALK M, KASTELEIN JJ, MURPHY RL et al.: Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS (2001) 15:2407-2414. (Pubitemid 34014609)
26. MURPHY R, THIRY A, MANCINI M, POKROVSKY V, ROZENBAUM W: Twelve weeks of atazanavir treatment reverses nelfinavir-associated hyperlipidaemia: results from BMS AI424-4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. San Diego, California, USA (2002). Abstract 15.
27. WANG S, MULVREY R, LAING N, LEET J, FLINT O, PARKER RA: Differentiation of atazanavir from other HIV-protease inhibitors in preclinical models of glucose uptake, lipogenesis and proteasome function. 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. San Diego, California, USA (2002). Abstract 10.
28. THOMPSON M, TASHIMA K, SCHOOLEY R et al.: Different impact on metabolic parameters of amprenavir/ritonavir regimens with tenofovir versus efavirenz. 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. San Diego, California, USA (2002). Abstract 45.
29. GALLI M, GERVASONI C, ADORNI F et al.: Factors associated with the development of high serum triglyceride levels in patients receiving two NRTI combinations. 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. San Diego, California, USA (2002). Abstract 40.
30. WALMSLEY S, MONTANER J, SAAG M, HILL A, BARYLSKI C, CHEN K: Nucleoside reverse transrciptase inhibitor treatment as a risk factor for hyperlipidaemia: results from the FOCUS trial. 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. San Diego, California, USA (2002). Abstract 52.
31. RHEW D, KIM M, BERNAL M, AGUILAR D, ILOUJE U, GOETZ MB: Association between protease inhibitors and increased cardiovascular risk: a systematic review. 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. San Diego, California, USA (2002). Abstract 56.
32. CURRIER J, TAYLOR A, BOYD F et al.: Coronary heart disease in HIV-infected individuals: associations with antiretroviral therapy. 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. San Diego, California, USA (2002). Abstract 54.
33. ILOEJE UH, YU-ISENBERG KS, VENTURA EP, TUOMARI AV: Treatment of HIV-associated dyslipidemia: a time trend analysis 1998-2001. 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. San Diego, California, USA (2002). Abstract 42.
34. ILOEJE UH, KAWABATA H, WU Y: Age and gender differences in treatment of antiretroviral treatment-associated dyslipidemia among HIV/AIDS patients. 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. San Diego, California, USA (2002). Abstract 43.
35. BARRIOS A, BLANCO F, GARCIABENAYAS T et al.: Effect of dietary intervention on highly active antiretroviral therapy-associated dyslipidemia. AIDS (2002) 16:2079-2081. (Pubitemid 35205273)
36. RAGHAVAN S, IQBAL S, LEVINE K, TANCO D, MINOLFO R, EL-SADR W: Effectiveness of supervised exercise programme on fat accumulation and metabolic levels in HIV-infected African-Americans and Latinos. 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. San Diego, California, USA (2002). Abstract 60.
37. GRUNFELD C, PANG M, DOERRLERW, SHIGENAGA JK, JENSEN P, FEINGOLD KR: Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J. Clin. Endocrinol. Metab. (1992) 74:1045-1052.
38. STEIN JH, MERWOOD MA, BELLEHUMEUR JL, SOSMAN JM: Effects of pravastatin on lipids and lipoprotein sub-fractions in patients receiving HIV protease inhibitors. 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. San Diego, California, USA (2002). Abstract 50.
39. DOSER N, KUBLI S, TELENTI A et al.: Efficacy and safety of fluvastatin in hyperlipidemic protease inhibitor-treated HIV-infected patients. AIDS (2002) 16:1982-1983.
40. VISNEGARWALA F, SAJJA P, RODRIGUEZ-BARRADDAS MC et al.: Inconsistent effects of lipid-lowering drugs in the management of HIV-associated dyslipidemias. 3rd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Athens, Greece (2001). Abstract 30.
41. MOYLE GJ, DATTA D, MANDALIA S, MORLESE J, GAZZARD BG: Matched case control study to evaluate risk factors for hyperlactataemia in HIV patients on antiretroviral therapy. 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. San Diego, California, USA (2002). Abstract 70.
42. LECLERQ P, DERRADJI M, COLOMBE B, LEVERVE XM: Lactate endogenous production is a good tool to evaluate mitochondrial dysfunction. 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. San Diego, California, USA (2002). Abstract 67.
43. ARENAS-PINTO A, GRANT AD, EDWARDS S, WELLER IVD: Lactic acidosis in HIV-infected patients: a systematic review of published cases. 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. San Diego, California, USA (2002). Abstract 64.
44. MALLAL S, NOLAN D, WITT C et al.: Association between presence of HLAB*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reversetranscriptase inhibitor abacavir. Lancet (2002) 359:727-32. (Pubitemid 34215071)
45. HETHERINGTON S, HUGHES AR, MOSTELLER M et al.: Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet (2002) 35:1121-1122. (Pubitemid 34270738)
46. MONDY K, LASSA-CLAXTON S, HOFFMANN M, YARASHESKI K, POWDERLY W, TEBAS P: Longitudinal evolution of bone mineral density (BMD) and bone markers in HIV-infected individuals. 9th Conference on Retroviruses and Opportunistic Infections. Seattle, Washington, USA (2002). Abstract 718-T.
47. NOLAN D, UPTON R, MCKINNON E et al.: Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir. AIDS (2001) 15:1275-1280. (Pubitemid 32592360)
48. DUBE MP, QIAN D, EDMONDSONMELANCON H et al.: Prospective, intensive study of metabolic changes associated with 48 weeks of amprenavirbased antiretroviral therapy. Clin. Infect. Dis. (2002) 35:475-481. (Pubitemid 34852578)
49. HILL A: Statistical power to detect drug toxicity in HIV clinical trials. 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. San Diego, California, USA (2002). Abstract 20.